High titer adeno-associated virus (AAV) production that is Cost-effective and Scalable

Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs. AAV has an efficacy and safety profile that makes it an ideal therapeutic vector—already part of several high-profile drug approvals in both the US and Europe. Yet, with this intensified interest in AAV therapies comes the need to scale-up viral production methods. As such, it’s imperative that successful viral production produce high titers that is cost-effective and scalable. During this webinar session, our presenter will highlight a scalable, high-titer, simplified AAV production in the AAV-MAX helper free AAV Production System.

 

 

Learning Objectives: